Lexeo Therapeutics (LXEO) EPS (Weighted Average and Diluted) (2022 - 2026)

Lexeo Therapeutics has disclosed EPS (Weighted Average and Diluted) across 5 years of filings, most recently posting -$0.25 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.25, up 74.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.32 (up 60.0% YoY), and the FY2025 annual result was -$1.86, up 39.81% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.25 for Q1 2026 at Lexeo Therapeutics, down from -$0.14 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $19.84 in Q4 2023 to a low of -$12.36 in Q3 2023.
• The 5-year median for EPS (Weighted Average and Diluted) is -$0.78 (2024), against an average of -$2.47.
• Across the five-year window, EPS (Weighted Average and Diluted) soared 323.93% in 2023 and tumbled 103.93% in 2024, its largest moves.
• Lexeo Therapeutics' EPS (Weighted Average and Diluted) stood at -$8.86 in 2022, then jumped by 323.93% to $19.84 in 2023, then sank by 103.93% to -$0.78 in 2024, then surged by 82.05% to -$0.14 in 2025, then slumped by 78.57% to -$0.25 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.25 (Q1 2026), -$0.14 (Q4 2025), and -$0.33 (Q3 2025), per Business Quant data.